Clinical Trials
123 trialsNCT02231749 2026-05-27
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT03899155 2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT07218926 2026-05-27
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
Phase 3 Recruiting
NCT03260894 2026-05-22
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT05043090 2026-05-22
SAMETA
AstraZeneca
Phase 3 Active not recruiting
NCT05208047 2026-05-22
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Phase 3 Active not recruiting
NCT03768063 2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT04633122 2026-04-03
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT05024214 2026-03-25
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Phase 1/2 Recruiting
NCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
NCT03673501 2026-02-05
INTRIGUE
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05245968 2026-01-20
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Taiho Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05734105 2025-12-17
INSIGHT
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT02401815 2025-02-14
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1/2 Completed
NCT04523272 2024-10-15
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Active not recruiting
NCT04409223 2024-02-09
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT05800106 2023-04-10
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT02420821 2023-01-30
IMmotion151
Hoffmann-La Roche
Phase 3 Completed
NCT02432846 2022-08-22
MERECA
Mendus
Phase 2 Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT01024920 2021-07-19
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Boehringer Ingelheim
Phase 2 Completed
NCT01694277 2020-12-08
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
Phase 3 Completed
NCT01673386 2020-10-27
TAURUS
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01984242 2019-12-23
IMmotion150
Hoffmann-La Roche
Phase 2 Completed
NCT00975806 2019-11-25
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
Celgene
Phase 1/2 Terminated
NCT00709995 2019-09-30
A Study for Participants With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01525550 2019-07-30
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 4 Completed
NCT01391130 2019-07-23
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Phase 2 Terminated
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT01396148 2019-03-27
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT01258348 2019-01-10
A Phase 1b Trial in Patients With Renal Cell Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01506336 2018-12-11
Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
AB Science
Phase 2 Completed
NCT00599313 2018-10-25
Phase II Sunitinib Prog Met AIPC
US Oncology Research
Phase 2 Completed
NCT00864721 2018-10-16
Sunitinib Non Small Cell Lung Cancer Patients Over 70
US Oncology Research
Phase 2 Completed
NCT00375674 2018-09-21
S-TRAC
Pfizer
Phase 3 Completed
NCT02386111 2018-07-26
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
Phase 1 Terminated
NCT01582672 2018-06-14
ADAPT
Argos Therapeutics
Phase 3 Terminated
NCT01829841 2018-05-03
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01265901 2017-10-12
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH
Phase 3 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed